Martin Jelsma is a political scientist who has specialised in Latin America and international drugs policy. In 2005, he received the Alfred R. Lindesmith Award for Achievement in the Field of Scholarship, which stated that Jelsma "is increasingly recognized as one of, if not the, outstanding strategists in terms of how international institutions deal with drugs and drug policy."...
Ernestien Jensema (1971) is a social anthropologist who has been working as a researcher and project coordinator with the Drugs & Democracy Programme of TNI since 2008. She focuses on issues related to the UN drug control system and the Drugs and Democracy Programme’s Asia project....
U.S. drug control officials have denounced Dutch drug policy as if it were the devil himself. One former U.S. Drug Czar said "you can't walk down the street in Amsterdam without tripping over junkies." In the Summer of 1998, however, one such denouncement turned into a small scandal. The first part of this chapter examines this incident as a window on the politics of drug policy. The second part offers a more general analysis of why U.S. drug control officials seem to be so threatened by the Dutch example.
Cannabis is the cutting-edge drug for reform, the only politically plausible candidate for major legal change, at least decriminalisation (removal of criminal penalties for possession) and perhaps even outright legalisation (permitting production and sale). Compared with other drugs, the harms, physiological or behavioural, are less severe and the drug is better integrated into the culture. Throughout Western Europe and in the Antipodes there is pressure for reductions in the punitiveness of the marijuana regime.
Economists have been among the leading critics of current drug policies, but this criticism does not mean they have reached a consensus about specific reforms. Although drug-policy researchers and economists in general seem opposed to prohibition, they are timid in their advocacy of decriminalization and even less supportive of legalization.
Following decades of rising cannabis use and talk of liberalisation, Switzerland had appeared poised to become the marijuana capital of Europe. The country still boasts some of the highest rates of cannabis use in Europe, but Switzerland's pot movement has taken a hit in the past few years: proposed liberalisation did not come to pass and enforcement has been on the rise.
Robin Room, Peter Reuter (RAND), Wayne Hall, Benedikt Fischer, Simon Lenton, Amanda Fielding
01 September 2008
Despite cannabis being the most widely used illegal drug, and therefore the mainstay of the ‘war on drugs’, it has only ever held a relatively marginal position in international drug policy discussions. Amanda Fielding of the Beckley Foundation decided to convene a team of the world’s leading drug policy analysts to prepare an overview of the latest scientific evidence surrounding cannabis and the policies that control its use. The report of the Beckley Foundation's Global Cannabis Commission is aimed at bringing cannabis to the attention of policymakers and guide decision making.
Most of the Dutch local councils that have so-called coffee shops which sell marijuana say they have no problem with the current policy of tolerating these outlets, according to a survey by NRC Handelsblad. The newspaper sent a questionnaire to the 105 local councils which, between them, have a total of 353 coffee shops. Of the two-thirds that responded, only 14 felt these establishments should be closed. But over 75 percent want the national government to regulate wholesale supply to the coffee shops.
The Dutch government should licence the growing and supply of marijuana to the country’s 700 or so coffee shops that sell cannabis, according to a group of around 30 Dutch mayors. This is the conclusion of the ‘cannabis summit’ at which the mayors discussed the country’s policy on soft drugs. The mayor of Eindhoven, Rob van Gijzel, said his city is prepared to run a ‘monitored pilot scheme’ to assess if a system of licenced growers reduces drugs-related crime.
This paper starts from the premise that, when a new psychoactive substance appears on the licit/illicit market in a country in Europe, legislators need to choose whether to bring it under control of the drug laws, and for public health reasons they may need to do so quickly. A comparative study of the systems and procedures finds that there are a variety of control methods available in the different countries, including the analogue and generic systems, as well as temporary emergency and rapid permanent scheduling procedures.
In 2001, Canada became the first country to adopt a formal system to regulate the medicinal use of marijuana — the Marijuana Medical Access Regulations. The policy allowed people suffering from terminal illnesses or severe conditions such as epilepsy, AIDS, multiple sclerosis and cancer to use the drug if it eased their symptoms. Some people would be able to grow marijuana themselves under strict guidelines.
Tom Kramer (1968) is a political scientist with 25-years of working experience on Myanmar and its border regions, which he has visited regularly since 1993. He first specialised in analysing ethnic conflict in Myanmar and the role of civil society to promote change. ...
There is a growing recognition around the world that the prohibition of drugs is a counterproductive failure. However, a major barrier to drug law reform has been a widespread fear of the unknown—just what could a post-prohibition regime look like?
The application of regulatory theory to the problem of illicit drugs has generally been thought about only in terms of ‘command and control’. The international treaties governing global illicit drug control and the use of law enforcement to dissuade and punish offenders have been primary strategies. In this paper the application of other aspects of regulatory theory to illicit drugs – primarily self-regulation and market regulation – are explored. There has been an overreliance on strategies from the top of the regulatory pyramid.
The regulation of khat, one of the most recent psychoactive drugs to become a globally traded commodity, remains hotly contested within different producer and consumer countries. As regimes vary, it has been possible to compare khat policies in Africa, Europe and North America from different disciplinary perspectives. The research established the significance of khat for rural producers, regional economies, as a tax base and source of foreign exchange. At the same time, khat as a psychoactive substance is associated with health and public safety problems that in turn are met with often ill-informed legislative responses. Bans have in turn lead to the criminalisation of users and sellers and illegal drug markets.
In the United States the discussion on the pros and cons of regulating cannabis is well advanced. The national television news programme CNBC has dedicated a website, Marijuana & Money, to the issue. “Many Americans support legalization and many states already permit medical use,” the site says. “An end to prohibition would generate billions in tax revenue and relieve the criminal justice system. But is it the right thing to do?”
Within the last decade the hitherto little known psychoactive substance of khat has emerged as a regional and international issue. In the Horn of Africa khat production has spurred an economic boom, but dramatic increases in consumption have raised public health concerns. Given the complexity of the topic spanning multiple academic disciplines and fields of professional practice, the need for a systematic overview is urgent.
'Save the country, legalise drugs.' Under this striking banner, two former Dutch government ministers (for foreign affairs and health) are launching their revolutionary plan. They estimate that more than half of all the costs of crime are related to drugs. They argue that by regulating their production and sale and imposing strict government supervision, drug crime will disappear. And they say that would lead to unprecedented savings for the police and judiciary.
The ban on recreational drugs promotes crime and is bad for public health. Austerity measures to cut public spending are a hot topic for debate everywhere in Europe. In the Netherlands, where a new parliament will be elected next month, several proposals to reduce spending by 30 billion euros are on the table. All of these proposals hit where it hurts, but one option could actually be a welcome relief: drug regulation. (See also: Former ministers: legalise all drugs!)